Journal profile · MEDICINE, RESEARCH & EXPERIMENTALPHARMACOL-PHARMACOLOGY & PHARMACY
Drug Delivery and Translational Research
ISSN 2190-393X · eISSN 2190-3948 · Springer US · GERMANY · 12 issues per year · Founded 2011
Drug Delivery and Translational Research: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 6.79; hybrid open access; APC about USD 4,690; median 107 days to acceptance (53 articles, last 24 months); 260 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Drug Delivery and Translational Research is published by Springer US and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Drug Delivery Systems, Advancements in Transdermal Drug Delivery and Nanoparticle-Based Drug Delivery, together about 40.6% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)
The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions. Research focused on the following areas of translational drug delivery research will be considered for publication in the journal. Designing and developing novel drug delivery systems, with a focus on their application to disease conditions; Preclinical and clinical data related to drug delivery systems;Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomesShort-term and long-term biocompatibility of drug delivery systems, host response; Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering;Image-guided drug therapy, Nanomedicine;Devices for drug delivery and drug/device combination products.In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTALPHARMACOL-PHARMACOLOGY & PHARMACY
Editor-in-chief Maria J. AlonsoPublisher website
Editorial board by country: 5 in mainland China (about 5%); most named United States 34, United Kingdom 6, South Korea 6, Canada 6, Mainland China 5 (99 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics15.7%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics14.6%
- Nanoparticle-Based Drug DeliveryMaterials Science10.3%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology8.3%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics6.7%
- Nanoplatforms for cancer theranosticsEngineering4.4%
- Dermatology and Skin DiseasesMedicine4.3%
- Inhalation and Respiratory Drug DeliveryMedicine3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 6.79LetPub ·
- Impact factor (publisher) 2025
- 6.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 7.5Publisher website ·
- CiteScore 2026-06
- 14.2LetPub ·
- SJR 2026-06
- 1.28LetPub ·
- SNIP 2026-06
- 1.33LetPub ·
- h-index
- 27LetPub ·
- h-index
- 92OpenAlex ·
- i10-index
- 1,341OpenAlex ·
- 2-year mean citedness
- 7.39OpenAlex ·
- Self-citation rate
- 1.4%LetPub ·
- Share of gold OA articles
- 39.34%LetPub ·
Volume
- Articles per year
- 252LetPub ·
- Downloads per year (publisher) 2025
- 1,400,000Publisher website ·
Articles by year OpenAlex count · 2,216 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 192 | 97 | 155 |
| 2025 | 260 | 128 | 1,391 |
| 2024 | 267 | 136 | 3,769 |
| 2023 | 215 | 96 | 3,808 |
| 2022 | 183 | 88 | 5,325 |
| 2021 | 223 | 97 | 9,139 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
107 daysMedian, submission to acceptance · P25–P75 72 days – 139 days
- Acceptance to online
- median 16 days (103 articles)
- Submission to online
- median 124 days
- Sample
- 53 articles with submission and acceptance dates (506 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to first decision
- 12 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,690 / EUR 3,890 / GBP 3,090 | — | — | |
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Other fees
- color figures in print
- Submission fee
- No submission fee
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- 150–250 words
- Keywords
- ≥ 4
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted15, with length limits
- editorialResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…Length not stated
- inspirational notes (by special invitation only)Inspirational Notes (by special invitation only) Inspirational Notes are short articles solicited by the editors that review the history and current status of a…Length not stated
- letterResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…Length not stated
- methodsMethods Articles describing new device designs and methods of delivery of bioactives with significant potential benefits over conventional methods of delivery a…Length not stated
- original researchResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…Length not stated
- original research articleResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…Length not stated
- research articleResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…Length not stated
- reviewResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…Length not stated
- review articleResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…Length not stated
- review articlesReview articles Authors are required to upload a separate "Review Proposal" file in Editorial Manager, in addition to their Cover Letter.Length not stated
- reviewsReviews Reviews considered for publication in this journal are written on current topics relevant to drug delivery and translational research, providing critica…Length not stated
- short communicationShort communications should report recent findings of high impact and should include a brief abstract and a combined narrative description of experimental metho…Length not stated
- short communicationsShort communications Short communications should report recent findings of high impact and should include a brief abstract and a combined narrative description …Length not stated
- technical noteResearch Articles Reports of original research on the science and technology of delivery of bioactives, especially studies with a translational focus, are encou…main text ≤ 4,000 words
- technical notesTechnical Notes A Technical Note is a short research article which permits the authors to share innovative ideas that have immediate impact on research and appl…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Conflict of interest Disclosure
Author contribution and competing interest statements required at submission. Model summary
When authors submit a manuscript, they are responsible for disclosing all financial and personal relationships that might bias their work. To prevent ambiguity, authors must state explicitly whether potential conflicts do or do not exist. Each author must indicate whether or not they have a financial relationship with the organization that sponsored the research. For each source of funds, both the…
Source ↗Publisher website ·- Data availability Data Availability
Data availability statement is optional. Model summary
This journal encourages authors to provide an optional statement of data availability in their article. Data Availability Statements should include information on where data supporting the results reported in the article can be found, including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study. Data availability statements can also indicate whether …
Source ↗Publisher website ·- Publication ethics Ethical standards
Ethics approval statement required for research involving human or animal subjects. Model summary
Manuscripts submitted for publication must contain a declaration that the experiments comply with the current laws of the country in which they were performed. Please include this note in a separate section before the reference list. Back to top
Source ↗Publisher website ·- License & copyright Copyright
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under a Creative Commons license. Details of the OA licences offered to authors can be found on the individual journal website, in the journal's How to publish with us guide. Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Drug Delivery and Translational Research, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer US
- Country or region
- GERMANY
- Language
- English
- Frequency
- 12 issues per year
- Founded
- 2011
- ISSN
- 2190-393X
- Electronic ISSN
- 2190-3948
- Society / sponsor
- Controlled Release Society
- Latest issue on the website
- Volume 16, Issue 9 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Drug Delivery and Translational Research
What CAS zone is Drug Delivery and Translational Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Drug Delivery and Translational Research is in Zone 3 of Medicine, and in Zone 3 of the minor category Medicine, Research & Experimental / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Drug Delivery and Translational Research?
The latest impact factor listed by LetPub is 6.79; CiteScore 14.2, h-index 92.
How long does peer review take at Drug Delivery and Translational Research?
Based on the dates recorded on 53 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 107 days (interquartile range 72–139 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Drug Delivery and Translational Research?
According to the journal's author guidelines: Abstract: 150–250 words; Keywords: ≥ 4; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Drug Delivery and Translational Research based?
Of the 99 board members whose country the journal's board page names, 5 (about 5%) are in mainland China; the countries named most often are United States (34), United Kingdom (6) and South Korea (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Drug Delivery and Translational Research?
According to LetPub and DOAJ records, Drug Delivery and Translational Research is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Drug Delivery and Translational Research open access, and what is the APC?
Drug Delivery and Translational Research is a hybrid journal. For open-access publication: APC about USD 4,690.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .